Neogenomics Stock Current Liabilities
| NEO Stock | USD 17.73 0.01 0.06% |
NeoGenomics fundamentals help investors to digest information that contributes to NeoGenomics' financial success or failures. It also enables traders to predict the movement of NeoGenomics Stock. The fundamental analysis module provides a way to measure NeoGenomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NeoGenomics stock.
As of the 29th of November 2024, Total Current Liabilities is likely to grow to about 101.1 M. Also, Non Current Liabilities Total is likely to grow to about 675.6 M. NeoGenomics | Current Liabilities |
NeoGenomics Company Current Liabilities Analysis
NeoGenomics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current NeoGenomics Current Liabilities | 40.06 M |
Most of NeoGenomics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoGenomics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NeoGenomics Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for NeoGenomics is extremely important. It helps to project a fair market value of NeoGenomics Stock properly, considering its historical fundamentals such as Current Liabilities. Since NeoGenomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NeoGenomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NeoGenomics' interrelated accounts and indicators.
Click cells to compare fundamentals
NeoGenomics Current Liabilities Historical Pattern
Today, most investors in NeoGenomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NeoGenomics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of NeoGenomics current liabilities as a starting point in their analysis.
NeoGenomics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
NeoGenomics Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, NeoGenomics has a Current Liabilities of 40.06 M. This is 97.71% lower than that of the Life Sciences Tools & Services sector and 92.44% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.49% higher than that of the company.
NeoGenomics Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoGenomics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoGenomics could also be used in its relative valuation, which is a method of valuing NeoGenomics by comparing valuation metrics of similar companies.NeoGenomics is currently under evaluation in current liabilities category among its peers.
NeoGenomics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NeoGenomics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NeoGenomics' managers, analysts, and investors.Environmental | Governance | Social |
NeoGenomics Fundamentals
| Return On Equity | -0.0838 | ||||
| Return On Asset | -0.0276 | ||||
| Profit Margin | (0.12) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 2.5 B | ||||
| Shares Outstanding | 128.36 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 99.63 % | ||||
| Number Of Shares Shorted | 3.63 M | ||||
| Price To Earning | 272.37 X | ||||
| Price To Book | 2.51 X | ||||
| Price To Sales | 3.54 X | ||||
| Revenue | 591.64 M | ||||
| Gross Profit | 187.9 M | ||||
| EBITDA | (17.61 M) | ||||
| Net Income | (87.97 M) | ||||
| Cash And Equivalents | 465.95 M | ||||
| Cash Per Share | 3.70 X | ||||
| Total Debt | 611.68 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 7.09 X | ||||
| Cash Flow From Operations | (1.95 M) | ||||
| Short Ratio | 4.64 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Price To Earnings To Growth | 3.02 X | ||||
| Target Price | 20.91 | ||||
| Number Of Employees | 2.1 K | ||||
| Beta | 1.18 | ||||
| Market Capitalization | 2.28 B | ||||
| Total Asset | 1.68 B | ||||
| Retained Earnings | (247.06 M) | ||||
| Working Capital | 500.51 M | ||||
| Current Asset | 82.36 M | ||||
| Current Liabilities | 40.06 M | ||||
| Net Asset | 1.68 B |
About NeoGenomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoGenomics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoGenomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoGenomics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving against NeoGenomics Stock
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out NeoGenomics Piotroski F Score and NeoGenomics Altman Z Score analysis. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.306 | Earnings Share (0.61) | Revenue Per Share 5.098 | Quarterly Revenue Growth 0.104 | Return On Assets (0.03) |
The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.